Dr Dirk Elston presented a comprehensive review of the top JAAD articles and findings from 2024. Dr Elston truly highlighted the major impact of JAAD with a presentation of slide after slide of groundbreaking articles. His presentation began with an important finding linking dupilumab to an increased risk of mycosis fungoides. He then discussed a study on diagnosing centrally located alopecia in patients of African descent, emphasizing that while central centrifugal cicatricial alopecia is a common diagnosis, up to half of these patients may also have pattern alopecia, suggesting that differential diagnoses should include causes considered in other populations. 

The presentation continued with studies addressing a wide range of topics: lentigo maligna margins on the head and neck, the safety profile of guselkumab in patients with psoriasis and a history of neoplasms or hepatitis, crisaborole for stasis dermatitis, roflumilast for seborrheic dermatitis, spesolimab and imsidolimab for generalized pustular psoriasis, skin cancer risks in UV phototherapy without psoralens, noninvasive treatments for cutaneous neurofibromas, deucravacitinib for scalp psoriasis, propranolol duration for infantile hemangiomas, and the impact of dupilumab on patch testing. 

Dr Elston also covered ongoing research published in JAAD, including eblasakimab trials for atopic dermatitis, apremilast for genital psoriasis, orismilast for moderate-to-severe psoriasis, povorcitinib and other treatments for hidradenitis suppurativa, the relationship between solvent exposure and systemic sclerosis, hyperbaric oxygen therapy for calciphylaxis, dermoscopy findings for lentigo maligna, comparisons of treatments for Bowen’s disease and extramammary Paget’s disease, M-PDT and lasers for acne vulgaris, ALA-PDT for rosacea, alpha-gal syndrome, and cross-reactions with biologics.